Clinical Trial Detail

NCT ID NCT01750918
Title BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements yes
Sponsors GlaxoSmithKline
Indications

colorectal cancer

Therapies

Fluorouracil

Panitumumab + Dabrafenib

Panitumumab + Trametinib + Dabrafenib

Panitumumab + Trametinib

Age Groups: adult

Additional content available in CKB BOOST